Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer

Clinical Cancer Research

Volumn 9, Issue 4, 2003, Pages 1253-1258

  Berns, Els M J J ^a,d   Klijn, Jan G M ^a   Look, Maxime P ^a   Grebenchtchikov, Nicolai ^b   Vossen, Rolf ^c   Peters, Harry ^a   Geurts Moespot, Anneke ^b   Portengen, Henk ^a   Van Staveren, Iris L ^a   Meijer van Gelder, Marion E ^a   Bakker, Bert ^c   Sweep, Fred C G J ^b   Foekens, John A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GENE PRODUCT; METHOTREXATE; PROTEIN P53; TAMOXIFEN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; DIAGNOSTIC VALUE; DRUG RECEPTOR BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; HORMONE RECEPTOR INTERACTION; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OPEN READING FRAME; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; SURVIVAL; TP53 GENE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASMS; ODDS RATIO; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0037386821     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Osborne, C. K. Steroid hormone receptors in breast cancer management. Breast Cancer Res. Treat., 51: 227-238, 1998.
2. Klijn, J. G., Berns, E. M., and Foekens, J. A. Other endocrine and biological agents in the treatment of advanced breast cancer. In: W. R. Miller and J. N. Ingle (eds.), Endocrine Therapy in Breast Cancer, New York, Marcel Dekker, 2002.
3. Klijn, J. G., Berns, P. M., Schmitz, P. I., and Foekens, J. A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr. Rev., 13: 3-17, 1992.
4. Piccart, M., Lohrisch, C., Di Leo, A., and Larsimont, D. The predictive value of HER2 in breast cancer. Oncology (Basel), 61: 73-82, 2001.
5. Berns, E. M., Foekens, J. A., Vossen, R., Look, M. P., Devilee, P., Henzen-Logmans, S. C., van Staveren, I. L., van Putten, W. L., Inganas, M., Meijer-van Gelder, M. E., Cornelisse, C., Claassen, C. J., Portengen, H., Bakker, B., and Klijn, J. G. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res., 60: 2155-2162, 2000.
6. Foekens, J. A., Look, M. P., Peters, H. A., van Putten, W. L., Portengen, H., and Klijn, J. G. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J. Natl. Cancer Inst. (Bethesda), 87: 751-756, 1995.
7. Luo, L. Y., Diamandis, E. P., Look, M. P., Soosaipillai, A. P., and Foekens, J. A. Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. Br. J. Cancer, 86: 1790-1796, 2002.
8. Foekens, J. A., Peters, H. A., Grebenchtchikov, N., Look, M. P., Meijer-van Gelder, M. E., Geurts-Moespot, A., van der Kwast, T. H., Sweep, C. G., and Klijn, J. G. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res., 61: 5407-5414, 2001.
9. Toi, M., Matsumoto, T., and Bando, H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol., 2: 667-673, 2001.
10. Van Meir, E. G., Polverini, P. J., Chazin, V. R., Su Huang, H. J., de Tribolet, N., and Cavenee, W. K. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat. Genet., 8: 171-176, 1994.
11. Pal, S., Datta, K., and Mukhopadhyay, D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res., 61: 6952-6957, 2001.
12. Linderholm, B. K., Lindahl, T., Holmberg, L., Klaar, S., Lennerstrand, J., Henriksson, R., and Bergh, J. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res., 61: 2256-2260, 2001.
13. Gasparini, G., Toi, M., Miceli, R., Vermeulen, P. B., Dittadi, R., Biganzoli, E., Morabito, A., Fanelli, M., Gatti, C., Suzuki, H., Tominaga, T., Dirix, L. Y., and Gion, M. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J. Sci. Am., 5: 101-111, 1999.
14. Hyder, S. M., Nawaz, Z., Chiappetta, C., and Stancel, G. M. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res., 60: 3183-3190, 2000.
15. Hyder, S. M. The role of steroid hormones on the regulation of vascular endothelial growth factor. Am. J. Pathol., 161: 345-346, 2002.
16. Ruohola, J. K., Valve, E. M., Karkkainen, M. J., Joukov, V., Alitalo, K., and Harkonen, P. L. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol. Cell. Endocrinol., 149: 29-40, 1999.
17. Nakamura, J., Savinov, A., Lu, Q., and Brodie, A. Estrogen regulates vascular endothelial growth/permeability factor expressiom in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. Endocrinology, 137: 5589-5596, 1996.
18. Schafer, J. M., Lee, E. S., O'Regan, R. M., Yao, K., and Jordan, V. C. Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice. Clin. Cancer Res., 6: 4373-4380, 2000.
19. Adams, J., Carder, P. J., Downey, S., Forbes, M. A., MacLennan, K., Allgar, V., Kaufman, S., Hallam, S., Bicknell, R., Walker, J. J., Cairnduff, F., Selby, P. J., Perren, T. J., Lansdown, M., and Banks, R. E. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res., 60: 2898-2905, 2000.
20. Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., and Kerbel, R. S. Effect of p53 status on tumor response to antiangiogenic therapy. Science (Wash. DC), 295: 1526-1528, 2002.